You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 42 No. 9, September 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  COMMENT
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Akathisia and Tardive Dyskinesia

Changing Concepts

Stephen M. Stahl, MD, PhD

Arch Gen Psychiatry. 1985;42(9):915-917.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is now 30 years since the introduction of neuroleptics into clinical practice, and we are still learning more about the effects of these drugs in our patients. On the positive side, research on second-generation antipsychotics such as BW234U,1 piquindone (R022-1319),2 the substituted benzamides,3 and others has given rise to the hope that control of psychotic symptoms may someday be accomplished with much less risk of akathisia, parkinsonism, and tardive dyskinesia than exists for currently marketed neuroleptics. Until that day, however, we will more and more be forced to deal with the increasingly troublesome short- and long-term side effects of the first-generation compounds.

The article by Barnes and Braude4 in this issue of the ARCHIVES deals with one of the relatively neglected side effects of the first-generation neuroleptics, namely akathisia. These authors boldly attempt to make an operational definition of neuroleptic-induced akathisia, to subtype it, to . . . [Full Text PDF of this Article]


Author Affiliations

From the Laboratory of Neuropsychopharmacology, Schizophrenia Biologic Research Center, Palo Alto (Calif) Veterans Administration Medical Center; and the Mental Health Clinical Research Center, Department of Psychiatry and Behavioral Sciences, Stanford (Calif) University. Dr Stahl is now with Merck, Sharp and Dohme Research Laboratories, Essex, England.


Footnotes

Accepted for publication Jan 4, 1985.

Reprint requests to Merck, Sharp and Dohme Research Laboratories, Terlings Park—Eastwick Road, Harlow Essex CM20 2QR United Kingdom (Dr Stahl).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.